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Abstract
BACKGROUND—The quality of medication use in older adults is suboptimal with a large
percentage of individuals not receiving recommended care. Most efforts to evaluate the quality of
medication use target high-risk drugs, appropriate treatment of prevalent chronic disease states, or
a set of predefined quality indicators of medication use, rather than the patient. It is also suggested
that racial differences in the quality of medication use may exist in older adults.
OBJECTIVE—To determine the prevalence, number, and types of medication-related problems
in older adults, examining the impact of race on quality medication use.
METHODS—A prospective cohort study involving in-home interviews and medical record
reviews of 200 community-residing older adults stratified by race (100 blacks, 100 whites)
conducted three times over 1 year. No intervention to address medication-related problems was
performed. The quality of medication use was reported as medication-related problems by clinical
pharmacists.
KEY RESULTS—Mean age was 78.3 (whites) and 75.5 (blacks), with the majority being female.
Although whites used more medications than blacks (11.6 versus 9.7; p < 0.01), blacks had more
medication-related problems per person than whites (6.2 versus 4.9; p < 0.01). All patients had at
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least one medication-related problem; common problems at baseline, 6 months, and 12 months for
both whites and blacks were undertreatment, suboptimal drug use, suboptimal dosing,
nonadherence, and less costly alternative available. Blacks had significantly higher rates of
nonadherence than whites (68% versus 42%; p < 0.01). Over the 12-month study, the number of
medication-related problems not only persisted but increased (adjusted p=0.0168).
CONCLUSIONS—Medication-related problems are prevalent in both black and white older
adults and persist over one-year. Blacks had more medication-related problems than whites,
including higher rates of nonadherence. These findings require further study to better understand
racial disparities in the quality of medication use in older adults and the impact of race on specific
medication-related problems.
Keywords
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INTRODUCTION
The quality of medication use in older adults falls below established standards; one study
suggests that only 62% of individuals receive recommended care.1
Quality problems of medication use are of particular concern in older adults who are more
likely to have multiple chronic diseases, visit multiple providers, and use multiple
medications, placing them at an increased risk of developing medication-related problems.
2,3 This, in turn, may compromise their health status, functional status, and quality of life.4,5
Not only do medication-related problems take their toll on the health and well being of older
adults, drug-related morbidity and mortality is costly, estimated to be $177 billion
annually.6,7 Table 1 outlines the main categories of quality problems of medication use and
associated medication-related problems.
Research on the quality of medication use often targets select medication-related problems
or pre-defined quality indicators of medication use.3,4,8,9 We recently proposed a framework
that offers a more comprehensive and patient-centered definition of the quality of
medication use.3 A comprehensive approach to evaluating medication use that takes into
account the whole person and all the medications a person may be taking may provide more
meaningful information upon which to intervene to improve the quality of medication use.
The extent of racial disparities on the quality of medication use in older adults remains
largely unknown. Older black adults have been found to have lower drug spending, use
fewer prescription medications, have higher rates of medication non-adherence, and higher
rates of underuse of necessary medications than whites.10–13 However, no study to our
knowledge has examined racial differences in the quality of medication use when quality is
reported as a composite of medication-related problems and takes into account all
medications a patient may or may not be taking3
The purpose of this study was to assess the prevalence, number, and type of medication-
related problems in black and white older adults at three points in time over a 12-month
period through in-home interviews and medical record reviews, examining the impact of
race on quality medication use. The study was specifically designed with no intervention to
evaluate the quality of medication use over one year in older adults receiving usual care.
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The detailed methods for this longitudinal study are described elsewhere.14 Briefly, this
study was a 12-month prospective cohort study in which 200 older adults stratified by race
(100 white, 100 black; determined via self report and medical record verification) who
resided independently in the community were recruited from the Department on Aging
Eldercare Program and 2 senior housing complexes located in Orange County, North
Carolina. Subjects met the following inclusion criteria: (1) white or black, (2) age ≥ 60
years; (3) residing independently in the community setting; (4) taking ≥3 regularly-
scheduled prescription and/or non-prescription medications; (5) able to read and speak
English; and (6) willing to participate, as indicated by providing informed consent and
HIPAA-compliant authorization for release of medical information. Patients were excluded
if they had ≥3 errors on a cognitive screening instrument or received clinical pharmacy
services within the past 6 months.15 Using the Eldercare Program contact list, the
pharmacists conducted a screening call with each older adult enrolled in the Eldercare
program to describe the study and invite them to participate in a baseline visit for
verification of eligibility and enrollment. Recruitment from the senior housing complexes
relied on individual response by telephone to posted flyers. Of 435 older adults screened via
telephone; 235 individuals were excluded because they were not eligible (105), could not be
reached by phone (72), refused to participate (44), or had died (14).14 Thus 200 patients
were enrolled into the study and interviewed by a pharmacist. The study was conducted
from April 2005 through August 2007. The Biomedical Institutional Review Board of the
University of North Carolina at Chapel Hill approved this study.
The study employed two pharmacists part-time with Doctor of Pharmacy degrees. One
completed residency training in geriatrics, is a board-certified pharmacotherapy specialist,
and has practiced as a clinical pharmacist in an outpatient, interdisciplinary geriatric practice
setting for 6 years; the other is an independent consultant pharmacist providing medication
management services to older adults in the community.
Data Collection and Measures
Data were collected at baseline, 6 months and 12 months. All measures used in this study
have been described in detail elsewhere.14 The measures include demographics; the short
test of functional health literacy in adults (S-TOFHLA), which categorizes patient’s ability
to read and understand health-related material as inadequate (0–16), marginal (17–22), or
adequate (23–36) health literacy; and an 8-item self-reported instrumental activities of daily
living (IADL) scale, where the score on each item 0 (completely dependent on others), 1
(some assistance required), or 2 (independence) was summed to give a total score that
ranged from 0 (poorest functional status) to 16 (best functional status).16,17
The quality of medication use was measured and reported as medication-related
problems.3,14 The study investigators developed a list of seven medication-related problems
following an extensive literature review; the measure was adapted from a previously
published model to incorporate current professional knowledge and clinical experience and
refined by study investigators over time.18–20,21 The underlying premise of this framework
was that the number of medication-related problems a person has may be a reflection of their
overall quality of medication use; the more problems, the poorer the quality of medication
use. The pharmacists used a 3-step implicit process to guide their assessment of medication-
related problems.14 The 3-step implicit process included 1) a comprehensive medication
review with the older adult, 2) a medical record review, and 3) clinical pharmacist
formulation of medication-related problems. During the comprehensive in-home medication
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review, the pharmacist recorded detailed information on medical conditions, medications,
and medication-taking behaviors. Following the home visit, the pharmacist reviewed the
patient’s medical record to abstract information on medications, medical conditions,
laboratory values, physician assessment of the individual’s medical conditions,
hospitalizations, and any information pertinent to assessing the quality of medication use.
For the final step, the pharmacist formulated an assessment of the quality medication use,
taking into account best research evidence (e.g., published literature, established indicators
of quality care, clinical practice guidelines), clinical expertise and patient values. This
assessment of quality took the form of a listing of potential medication-related problems for
each individual (Table 1).
Statistical Analysis
The sample size estimation for our study was based on confidence interval (CI) widths and
detecting meaningful differences between whites and blacks in the proportion of individuals
with ≥1 medication-related problem at baseline. A sample size of 100 per group met the
conservative “sufficiently large” criterion formula21: n · p ≥10 or n (1−p) ≥10
where n is the sample size and p is the prevalence of ≥1 medication-related problem
allowing the use of the normal distribution for calculation of CIs. This sample size resulted
in 95% CI half-widths of 6% to 10% for prevalences ranging from 10% to 90% and
provided an 80% power to detect absolute differences of ≥14% to 21% between whites and
blacks depending on the prevalences in the 2 groups (α = 0.05).
Descriptive statistics are presented and comparisons were made by race (oversampled blacks
to specifically address racial differences.) using two sample t-tests (continuous data) or chi-
square tests of association (categorical data). The two primary outcomes identified a priori
were: (1) overall prevalence of medication-related problems in the population for blacks and
whites (proportion of subjects with any of the medication-related problems); and (2) average
number of medication-related problems per person for blacks and whites. Secondary
outcomes were the prevalence and average number of problems broken down by the seven
individual medication-related problems for blacks and whites.
We used generalized linear mixed models to analyze the two primary endpoints of
prevalence and number of medication related problems. The primary exposure of interest
was race. Models were adjusted for a fixed pharmacist effect, to adjust for pharmacist
variability, and for the following covariates identified a priori based on published literature:
number of baseline medications; health literacy, defined as S-TOFHLA < 17; age; and
gender. For the primary outcomes of interest, statistical significance was achieved at p≤0.05.
No formal corrections for multiple testing were conducted for the secondary outcomes of
interest. However, we were conservative in interpreting the findings of these secondary
outcomes; statistical significance was reached at a level of 0.01, while tests with 0.01 <p-
value ≤ 0.05 were only considered suggestive of a relationship. All analyses were conducted
using SAS version 9.1 (SAS, Cary, NC).
RESULTS
Baseline demographic characteristics for the 200 subjects are presented in Table 2. The
majority of participants in both groups were female (77%). Whites were significantly older,
had more education, and were more likely to live alone. Whites used more medications (11.6
versus 9.7, p<0.01), had a greater number of chronic conditions (8.4 versus 7.4, p=0.01), and
used more physicians (3.6 versus 2.8, <0.01), compared to blacks (Table 3). In addition,
more whites maintained a written list of their medications than blacks (30% versus 16%,
p=0.02), while a higher percentage of blacks could not purchase their medications due to
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cost (28% versus 12%, p<0.01). Whites were more likely than blacks to have adequate
health literacy (58% vs. 29% p<0.01).
Prevalence of Medication-Related Problems
All patients had at least one medication problem at baseline, 6 months, and 12 months.
Common problems at baseline, 6 months, and 12 months for both whites and blacks were
undertreatment, suboptimal drug use, suboptimal dosing, nonadherence, and less costly
alternative available (Figure 1).
Some differences in the prevalence of medication-related problems between blacks and
whites are worth noting (Figure 1). First, not only was the prevalence of “a less costly
alternative available” significantly different between blacks (49%) and whites (46%) at
baseline after adjusting for fixed pharmacist effect, baseline number of medications, age,
gender, and health literacy (p<0.0001), there was also a significant increase in the
prevalence over the 12-month study. Second, a significant difference in the prevalence of
nonadherence between blacks (68%) and whites (42%) at baseline was observed after
adjusting for the same covariates (p=0.003); the rates of nonadherence slightly increased
over the 12-month study to 71% for blacks and 48% for whites; however, this was not found
to be statistically significant (p=0.32). Finally, although there was no significant difference
in the prevalence of suboptimal drug use between blacks and whites at baseline, after
adjusting for covariates, the data suggests that the prevalence of suboptimal drug use
increased over time (p=0.03), with the most notable increases among white older adults.
Number of Medication-Related Problems
Overall, whites had on average fewer number of medication-related problems at baseline
than blacks (mean (SD): 4.9 (2.7) whites vs. 6.3 (3.2) blacks; adjusted p=0.0004) (Table 4).
Over the 12-month study, the number of medication-related problems persisted and actually
increased over time (adjusted p=0.0168) in whites and blacks. Most of the increase in
number of problems reflects use of suboptimal drugs and use of expensive drugs where less
costly alternatives exist.
Among the individual problems, a significant difference between blacks and whites in non-
adherence remained after adjusting for pharmacist, number of medications, health literacy,
age and gender (p=0.005). There was also a significant increase in the use of suboptimal
drugs over time (p=0.001). In addition, some borderline results are worth noting: the
increase over time in the problem of “less costly alternative available” (p=0.02), the
differences between blacks and whites with respect to this problem at baseline (p=0.07), and
the trend towards blacks having significantly more problems at baseline related to the need
for medication monitoring (adjusted p=0.06) (Table 4).
Since nonadherence was such a large component of the overall number of medication-
related problems and was the only problem that was significantly different between blacks
and whites after covariate adjustment, we conducted a sensitivity analysis. We removed
nonadherence from the list of medication-related problems, and reran the model. While the
differences was not as large, the mean number of medication-related problems remained
significantly greater for blacks than whites (4.34 versus 3.97; adjusted p=0.037).
DISCUSSION
This study demonstrates that medication-related problems are prevalent in community-
dwelling older adults; medication-related problems affect both blacks and whites, with racial
disparities observed in both the prevalence and number of medication-related problems; and,
with usual medical care, medication-related problems persist over one year.
Roth et al. Page 5













Overall, the average number of medication-related problems identified in our study was 6.3
for blacks and 4.9 for whites. The higher number of medication-related problems
documented in our study compared to previous studies may be due to a several
factors.21, 23,24 First, previous assessments of medication use often target patients with
specific chronic conditions or pre-defined quality indicators. We examined medication-
related problems across all chronic and acute diseases, taking into account the whole person.
Such an approach is more likely to help clinicians better assess chronic conditions and
implement strategies to improve older adults’ health. Second, most studies have focused on
the community pharmacy setting, where pharmacists rely on patient interviews and
prescription records in formulating an assessment of medication-related problems. In our
study, pharmacists relied not only on information gathered from the patient during a
comprehensive medication review, but gathered information from inspection of pill bottles,
and, most notably, from the patient’s medical record. Thus, we had more information and a
more complete picture of the patient when formulating assessments of medication use.
We observed racial differences in the quality of medication use. Several studies have
documented lower rates of prescription drug spending in blacks compared to whites, use of
fewer medications in blacks compared to whites, higher rates of medication nonadherence in
blacks compared to whites, and higher rates of medication underuse in blacks compared to
whites.10–13 Our findings are unique in that racial differences were found in the overall
quality of medication use. Blacks had significantly more medication-related problems at
baseline than whites (6.3 compared to 4.9, p=0.0003); a difference that persisted over the
12-month study, even after adjusting for health literacy, baseline number of medications,
age, and gender. In addition, racial disparities were noted in the prevalence of several
medication-related problems, including nonadherence and use of an expensive drug when a
less costly alternative was available, with a trend toward some difference in the need for
medication monitoring. Furthermore, when nonadherence was removed from the overall
model the mean number of medication-related problems remained significantly greater for
blacks than whites (4.34 versus 3.97; adjusted p = 0.037) at baseline, suggesting that other
disparities in the quality of medication use do exist. Future studies will need to more closely
examine disparities in the quality of medication use between blacks and whites and the
impact of such disparities on health outcomes as well as elucidate factors that may be
contributing to these disparities and the implications this may have on the design of
interventions to improve outcomes.
The main findings from the study are important for several reasons. First, all of our patients
were followed in primary care practices receiving what we would consider “standard of
care”, yet medication-related problems were identified in both blacks and whites and
persisted. This suggests that strategies to identify and resolve medication-related problems
in the outpatient setting are needed.25 Second, racial differences in blacks and whites were
noted, with blacks having significantly more medication-related problems overall than
whites. This is not entirely surprising considering that racial disparities have been previously
documented with respect to underuse of needed medications as well as medication
nonadherence. Although further studies are needed to examine differences between blacks
and whites with respect to specific medication-related problems, the study findings raise
some important clinical considerations. Are there medication-related problems of particular
concern in blacks that warrant further investigation? Should interventions to evaluate and
manage medications in older adults differ based on race?
There are several limitations of our study. First, although we report trends toward significant
differences between blacks and whites with respect to specific medication-related problems
(e.g., less costly alternative available, medication monitoring needed), it is important to note
that the sample size within each of these categories is quite small both in overall number and
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in terms of change. With such small samples we are limited in our ability to detect
meaningful differences between blacks and whites as it relates to specific medication-related
problems and to adjust for important covariates that might explain any racial differences.
Second, we reported that over the 12-month study the number of medication-related
problems persisted and actually increased over time (adjusted p=0.0168) in whites and
blacks. Although beyond the scope of this paper, clearly, additional studies would be needed
to further evaluate the increase in problems noted as well as any impact of race on a rise in
problems. Third, we excluded older adults with cognitive impairment, a group at high risk of
medication-related problems. Fourth, it was impossible to blind pharmacists to patient race.
Fifth, despite our attempts to standardize their assessment, one pharmacist documented a
mean of 1.6 more medication-related problems per patient than the other. Although we
adjusted for a fixed pharmacist effect in our analyses, the potential variability in
pharmacist’s assessments of medication-related problems will need to be considered in
designing future studies. We recently completed reliability testing of the framework of
medication-related problems among clinical pharmacists, using three paper-based clinical
cases; there was substantial to almost perfect agreement in pharmacist identification of MRP
categories (k=0.68–0.74) compared to a gold standard key. Additional inter-rater reliability
testing is being conducted as part of an ongoing longitudinal intervention study. We
continue to believe that an implicit framework for assessing medication-related problems in
older adults remains the most appropriate method for assessing the overall quality of
medication use for both clinical and research purposes.3 Finally, it will be important in
future studies to determine physician agreement with the clinical pharmacist’s assessment of
medication-related problems and their acceptance of recommendations to optimize
medication therapy. These next steps will serve to strengthen the implicit measurement of
the quality of medication use as we work toward a framework for assessing medication-
related problems that is not only well defined and reliable, but valid.
CONCLUSION
Medication-related problems are prevalent in both black and white older adults and persist
over one-year. Blacks had more medication-related problems than whites, including higher
rates of nonadherence. Moreover, with no targeted intervention to address the quality of
medication use, medication-related problems persist and appear to rise over time in both
black and white older adults. These findings require further study to better understand racial
disparities in the quality of medication use in older adults and the impact of race on specific
medication-related problems.
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Prevalence of Medication-Related Problems over the 12-month Study
Significant differences between race at baseline: *p≤ 0.001 for race +p≤ 0.05 for race
Significant increase in a medication-related problem over time: **p≤0.001 for
time ++p≤0.05 for time
All data adjusted for fixed pharmacist effect and baseline number of medications, health
literacy, age, gender.
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Table 1
The Quality of Medication Use3,14,22
Medication-Related Problem Definition
Suboptimal Drug The individual is receiving a drug that has no indication, is not effective, or is potentially not safe
(i.e., potential for harm exceeds potential for benefit).
Suboptimal Dose, Duration, Frequency,
or Administration
The individual is taking an appropriate medication, but the dose, duration, frequency or
administration is not optimal to achieve desired response, or has the potential for harm.
Adverse Drug Events The individual is experiencing an actual adverse consequence at the time of the interview that is
attributed to a drug or the inappropriate use of a drug.
Nonadherence* The individual has not filled a prescription, is not taking a drug, or is not using a drug as
prescribed, whether intentional or unintentional.
Less Costly Drug Available The individual is prescribed a medication for which a less costly, equally effective and safe drug is
available, and preferred by the patient, but the patient is receiving a more expensive product; or
the patient could benefit from prescription savings, but is not receiving eligible benefits and
desires to.
Undertreatment The individual has a medical condition or risk factors for a disease that would benefit from drug
therapy (clear indication) and the patient has no contraindications to the drug, but the drug was not
prescribed.
Suboptimal Medication Monitoring The individual is receiving a drug and monitoring is recommended (according to established
practice guidelines) to assess response to therapy or prevent harm, but the monitoring has not been
done.
*
We used 2 methods to assess nonadherence: the primary assessment (leading to identification of a medication-related problem of nonadherence)
was the clinical pharmacist implicit assessment of adherence for each medication a person was taking (i.e., adherent, nonadherent)following the
comprehensive medication review 14 and a validated patient self-report measure.37 Because no gold standard exists for measuring nonadherence,
we relied on multiple methods of assessment.
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Table 2
Demographic and baseline characteristics of community-residing older adults (n = 200)
White (n = 100) Black (n = 100) P-value
Age, mean (SD), y 78.3 (8.2) 75.5 (8.5) 0.02
Female, % 72 81 0.13
Education, highest level completed, % <0.001
 Elementary 8 24
 Some high school 6 19
 High school graduate 21 35
 Some college or technical school 24 12
 College graduate 18 6
 Postgraduate 23 4
Living alone, % 64 49 0.03
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Table 3
Medication and health-related characteristics of community-residing older adults (n = 200)
White (n = 100) Black (n = 100) P-value
Medications, * mean (SD); range 11.6 (5.0); 3–26 9.7 (4); 4–21 0.003
Chronic conditions, † mean (SD); range 8.4 (3.1); 2–19 7.4 (2.8); 2–18 0.01
Physicians, mean (SD); range 3.6 (1.8); 1–9 2.8 (1.5); 0–8 <0.001
Pharmacies, mean (SD); range 1.3 (0.6); 1–3 1.3 (0.5); 1–3 0.42
Has help with medications, % 16 16 1.00
Uses medication aid ‡, % 70 57 0.06
 Pill box, % 47 50 0.67
 Written list of medications, % 30 16 0.02
Shows written list to physician, % 18 11 0.16
Has some form of prescription drug coverage, % 91 94 0.42
Could not purchase meds due to cost, % 12 28 0.005
Short-test of functional health literacy in adults (S-TOFHLA) §; mean (SD); range 24.2 (10.6); 0–36 14.8 (11.9); 0–35 <0.001
 Adequate (%) 58 29
 Marginal (%) 12 13
 Inadequate (%) 30 58
Lawton Instrumental Activities of Daily Living Scale (IADLs) ||; mean (SD); range 13.7 (3.0); 1–16 13.5 (3.0); 4–16 0.69
*
Includes all medications (i.e., prescription, over-the-counter, and complementary and alternative medications).
†
Defined as any chronic condition documented in the medical record.
‡
Does not add up to 100%, since patients may have been using more than one medication aid.
§
Scores range from 0 to 36 and are categorized as inadequate (0–16), marginal (17–22), or adequate (23–36) health literacy.
||
Scores range from 0 (low function, dependent) to 16 (high function, independent).
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